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EFFICACY OF VITAMIN D TREATMENT IN PEDIATRIC PATIENTS WITH 
CROHN'S DISEASE AND ULCERATIVE COLITIS 
NADEZHDA BULEKOVA 
ABSTRACT 
Rising rates of urbanization and the global trend towards a more Western 
lifestyle correlates with increased incidence of both Vitamin D deficiency and 
Inflammatory Bowel Disease (IBD). The Vitamin D Hypothesis is the most 
current and prevalent theory that explains the rising cases of IBD. This 
hypothesis postulates that decreased ultraviolet radiation and dietary variety 
predispose certain populations to develop IBD. Vitamin D has an active role 
within the immune system, suppressing the development and function of pro-
inflammatory T helper cells while promoting the development and action of 
immunotolerant regulatory T cells. IBD patients receive pharmaceutical 
immunotherapies that antagonize pro-inflammatory markers.  Though Vitamin 
D is typically prescribed to support skeletal development, it may also be 
considered an adjunct therapy to prevent gastrointestinal flares in patients with 
IBD. However, the current standard of care for treating Vitamin D deficiency is 
prescribing daily Vitamin D supplements. On average, children exhibit poor 
compliance when prescribed a daily dosing regimen, especially when they do 
 
 vi
not experience a clear, direct benefit after taking their daily dose. An alternative 
to the daily dosing regimen is a high-dose, interval regimen of Vitamin D 
supplementation. Recent studies have demonstrated that high doses of Vitamin 
D are safe and effective at raising serum Vitamin D levels to optimal levels (40-60 
ng/mL) in the pediatric population. Moreover, IBD patients with optimal 
Vitamin D levels appear to experience significantly fewer gastrointestinal flare-
ups and hospitalizations. There is little existing research reporting on the use of 
high-dose, interval Vitamin D supplementation.  As such, more longitudinal 
studies need to be performed to assess not only patients’ Vitamin D status but 
also their levels of relevant immunological markers in their serum, such as pro-
inflammatory cytokines and regulatory T cells. These efforts would enable 
researchers to definitively conclude the effectiveness of high dose interval 
Vitamin D supplementation to raise serum Vitamin D levels and assess the 
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Inflammatory Bowel Disease – Crohn’s Disease and Ulcerative Colitis 
 Inflammatory bowel disease (IBD) is a chronic idiopathic disease 
characterized by immune-mediated damage to the lining of the gastrointestinal 
system. The two most common forms of IBD are Crohn’s Disease (CD) and 
ulcerative colitis (UC). Table 1 summarizes the main similarities and differences 
between CD and UC. 
 
Table 1. Comparison of CD and UC 
Disease Crohn’s Disease Ulcerative Colitis 
Cause Idiopathic Idiopathic 
Part of GI 
tract affected 
Anywhere from mouth to 
anus 
Colon 
Symptoms Abdominal pain, diarrhea, 
growth failure, weight 
loss, abscess, fistula 














 The incidence and prevalence of CD and UC are rising worldwide, 
driving the need to develop strategies that prevent and treat these potentially 
disabling disorders. There are a few theories that attempt to explain the 
increasing number of patients with IBD. One major factor, but not a sufficient 
factor, is genetics. A quarter of patients with IBD  have a first or second-degree 
relative with either CD or UC (Cooney and Jewell 2009).  The relative risk of 
siblings developing IBD ranges from 16.6 to 36.5, depending on the specific type 
of IBD and underlying (fraternal vs. identical twins) genetics (Satsangi et al. 
1998). Patients with IBD and their relatives may manifest variance and 
vulnerability in the genes regulating the adaptive immune system. As such, 
populations of T helper cells contribute to acute and chronic inflammatory 
responses by producing and secreting the pro-inflammatory cytokine interleukin 
17 (IL-17) (Yasuda, Takeuchi, and Hirota 2019). Any dysregulation of the genetics 
governing this otherwise tightly regulated inflammatory/anti-inflammatory axis 
results in the mucosal inflammation observed in patients with IBD.  
A second theory explaining the pathogenesis of IBD focuses on changes in 
the environment prompted by global urbanization. Western societies have 
historically reported a more significant percentage of IBD cases than elsewhere in 




in countries transitioning to more urban/Western lifestyles, including India and 
Japan (Braus and Elliott 2009). Interestingly, IBD prevalence is also related to 
increasing latitude. This may be related to the decreased amount of months spent 
in higher ambient UV radiation (Holmes, Xiang, and Lucas 2015). Figure 1 shows 







Figure 1. Incidence rate of CD and UC globally. Adapted from (Ng et al. 2013) 
A. World map of CD incidence 
B. World map of UC incidence 
 
Although there may be a correlation between the number of IBD cases and 
latitude, the geographical and environmental impact on IBD pathogenesis 
remains unclear, primarily due to poorly defined geographical locations and the 
application of inconsistent diagnostic criteria across studies. 
 Despite the unclear connection between geography and IBD, it seems clear 
that recent urbanization trends in developing countries, similar to the lower 
ambient UVR in higher latitude countries, have resulted in decreased dermal 
Vitamin D production. The Vitamin D Hypothesis is a relatively new idea within 
the realm of IBD etiology. This hypothesis postulates that with lower exposure to 
UVR and lower serum Vitamin D levels, subjects are more likely to be 
predisposed to conditions like IBD. The Vitamin D Hypothesis is based on the 
numerous reports that lower mean serum 25(OH)D levels are observed in 
patients with UC and CD than healthy controls (Li et al. 2019). Factory and office 
workers in industrialized or industrializing countries are indoors most of the day 




2 summarizes the process through which UVR converts a precursor of Vitamin D 
in the skin to its active forms, a key one being 25(OH)D.  
 
 
Figure 2. Vitamin D metabolism. Taken from (Christakos et al. 2010) 
In areas where the general population is less exposed to UVR, not only is the risk 
for developing IBD higher, but disease severity is greater (Ardesia, Ferlazzo, and 
Fries 2015). However, the observed correlation does not prove causation between 
lower Vitamin D levels and the risk of developing IBD. Low serum levels of 
25(OH)D are nevertheless associated with an increased risk of hospitalizations 




cannot definitively determine if lower Vitamin D levels contribute 
mechanistically to the onset of IBD, the importance of adequate Vitamin D levels 
in patients with either CD or UC is undeniable. 
 
Current IBD Treatments  
The lack of a clear understanding of the precipitating factors contributing 
to the onset of IBD has prevented the development of definitive therapies.   As a 
result, clinicians rely on treatments that slow disease progression and prevent 
acute flares in disease activity. The monoclonal antibodies infliximab and 
vedolizumab target TNF-alpha cytokines and integrin a4b7, respectively. 
Infliximab blocks an adverse autoimmune reaction by binding to a specific pro-
inflammatory cytokine, and vedolizumab operates by preventing gut-selective 
inflammatory activity. Although clinically effective, monoclonal treatments are a 
relatively new class of agents to the market and cost over $20,000 per year per 
patient. Therefore, access to these drugs may be limited by this considerable 
financial barrier, leaving many patients to opt for less effective but less costly 
treatment alternatives.  
Patients with CD and UC are often diagnosed in their adolescent years 




and bloody diarrhea. Poor nutrition and food energy intake result in 
malnutrition and fatigue, which leads to impaired linear growth and pubertal 
and cognitive development. Not only do these symptoms negatively impact a 
patient’s quality of life during adolescence, but IBD also increases the risk of 
colon cancer in adulthood. Therefore, it is imperative to identify effective 
approaches to prevent and treat IBD in children and young adults. The next 
section explores how Vitamin D could be of significant benefit to patients with 
CD and UC. 
 
Role of Vitamin D in Immune System Function 
Vitamin D deficiency has been linked to multiple diseases comorbid with 
dysregulated immune function, including IBD, multiple sclerosis, and lupus 
(Aranow 2011). One of the active forms of vitamin D, 1,25(OH)D, interacts with 
vitamin D receptors (VDR) in numerous cell types throughout the body.  T cells 
are central to the adaptive immune responses (Kongsbak et al. 2013). The helper 
and regulatory T cells responsible for initiating and suppressing autoimmune 
responses, respectively, both contain functional VDRs (Cosmi et al. 2014). Th1 
and Th17 T helper cells release pro-inflammatory cytokines. In contrast, Th2 




invading antigen (Romagnani 1999). Vitamin D has been shown to modify the T 
cell response by suppressing Th1 and Th17 cells and promoting the development 
of Th2 and Treg cells (Boonstra et al. 2001) (Fawaz et al. 2016) (Şıklar et al. 2016). 
As a result, Vitamin D indirectly suppresses an exaggerated inflammatory 
response in favor of one the is more regulated. Figure 3 summarizes the balance 




Figure 3. Vitamin D and T cells. Sufficient serum concentrations of 25(OH)D promote 
an immune response more tightly regulated by Th2 and Treg. Insufficient serum 
concentrations of 25(OH)D results in a less regulated immune response that is 
orchestrated by Th1 and Th17. Taken from (Hewison 2012). 
 
Figure 4 visualizes, in greater detail, the pathways by which vitamin D acts to 
prevent an inflammatory immune response. Vitamin D acts as an 




more tolerant T cells. Moreover, by suppressing the development and action of 
Th1 cells, Vitamin D also indirectly suppresses the release of TNF-alpha, one of 
the main pro-inflammatory cytokines. As discussed earlier, a common 
monoclonal antibody used to treat Crohn’s Disease is infliximab, which binds to 
and thus prevents the action of TNF-alpha. To a similar end, Vitamin D could 
potentially contribute as an adjunct therapy to infliximab by decreasing the 
amount of TNF-alpha produced in the first place. 
 
Figure 4. Effect of Vitamin D on the Adaptive Immune System. Taken from (Sassi, 





 Existing data, therefore, support a characterization of Vitamin D as an 
immunomodulator and anti-inflammatory agent. Many patients with IBD exhibit 
a deficiency (less than 30 ng/mL) in serum Vitamin D concentrations (Li et al. 
2019). However, a concentration greater than 30 ng/mL is likely necessary for 
patients to experience Vitamin D's significant immunomodulatory effects. More 
recent literature suggests that it may be necessary to drive serum Vitamin D 
concentrations above 40 ng/mL to anticipate meaningful changes in immune 
function (Weydert 2014). Therefore, targeting a patient’s serum Vitamin D 
concentration in the 40-60 ng/mL range is likely optimal for both bone and 
immune health in patients with IBD patients.  Consistent with this hypothesis, 
the data from a  retrospective study found that patients with IBD and low serum 
Vitamin D levels have a greater risk of developing cancer, especially colorectal 
cancer (Ananthakrishnan et al. 2013). Patients with IBD and 25(OH)D deficiency 
are almost twice as likely to develop cancer relative to those who are serum 
25(OH)D sufficient. Table 2 defines the different ranges of serum Vitamin D 






Table 2. Defined categories of serum Vitamin D levels 
Toxicity >150 ng/mL 
Maximum upper limit 100 ng/mL 
Optimal range 40-70 ng/mL 
Sufficient >30 ng/mL 
Insufficient 21-29 ng/mL 
Deficient <20 ng/mL 
Adapted from (Weydert 2014). 
 
With the increased risk for future cancer, delayed growth, and pain, pediatric 
patients with IBD, need a sufficient Vitamin D regimen to raise and maintain 
their serum Vitamin D to optimal levels. Thus, more clinical IBD research must 
focus on Vitamin D treatment, which represents a low-cost, adjunct therapy for 
patients with CD and UC. This literature thesis will explore recent IBD research 
studies focused on increasing serum Vitamin D and investigating a high-dose 
interval Vitamin D therapy that may prove beneficial for children, adolescents, 






CURRENT VITAMIN D THERAPY 
Vitamin D to treat Iron Deficiency Anemia 
Current therapy for patients with IBD includes monitoring iron status to 
prospectively identify and treat patients at risk for iron deficiency or the 
subsequent development of anemia (Jimenez and Gasche 2019). Access to 
adequate iron stores is necessary to carry out normal bodily functions, including 
oxygen transport, nuclear deoxyribonucleic acid (DNA) synthesis, and 
mitochondrial electron transport (Abbaspour, Hurrell, and Kelishadi 2014). 
Patients suffering from iron deficiency anemia (IDA) often lack energy.  This 
fatigue can disproportionally affect pediatric patients.  The added requirements 
necessary to ensure adequate growth and development also make pediatric 
patients particularly vulnerable to acute and chronic nutritional macro and 
micronutrient deficiencies. Current treatment involves either oral or intravenous 
supplementation with iron to restore normal hemoglobin levels, ferritin, and 
hepcidin. Data from a retrospective study over 11 years demonstrated an average 
increase in hemoglobin levels by 2g/dL (95% CI 1.5-2.5) after oral iron 
supplementation in pediatric patients with IBD (Egberg et al. 2018).  
Although iron supplementation can treat IBD complications, including 




patients with active IBD. Optimal therapies would address nutritional status and 
immune dysregulation in patients with IBD. There is a clear correlation between 
serum Vitamin D, hemoglobin, and hepcidin levels in pediatric patients, as 
shown in Figure 5 (MS et al. 2017). Increased hepcidin levels inhibit the apical 
transport of iron from enterocytes in the GI tract by blocking the ferroportin 
channel located on the cell's basolateral surface. Thus, the production and 
secretion of ferroportin exacerbate IDA in patients with IBD. Adequate Vitamin 
D levels are correlated with lower levels of hepcidin and higher levels of 
hemoglobin. Furthermore, Vitamin D deficiency in mothers is associated with 
lower Vitamin D levels in their children.  The decreased Vitamin D correlated 
with lower ferritin and hemoglobin levels and increased hepcidin levels (Cihan 





Figure 5: Hemoglobin (A) and hepcidin concentrations with corresponding 95% 
confidence intervals, by 25(OH)D concentration (Taken from MS et al. 2017) 
(A) Data was controlled by age, sex, race, insurance status, inflammation, and disease 
duration. Patients with Vitamin D concentrations <30 ng/mL had significantly lower 
hemoglobin concentrations than those with Vitamin D concentrations of ≥30 ng/mL (P = 
0.03). 
(B) Data was controlled by age, sex, race, insurance status, inflammation, and disease 
duration. Patients with Vitamin D concentrations <30 ng/mL had significantly higher 







Low Daily Supplementation 
  The current recommendation for Vitamin D supplementation in the 
general population ranges from 400-2000 IU per day, depending on various 
factors such as age, disease status, and body weight (Pludowski et al. 2018). 
Using these levels, Pappa et al. (2014) compared the effects of daily 400 IU, 1,000 
IU, and 2,000 IU Vitamin D supplementation in patients with IBD. Specifically, 
they randomized patients to receive either 400 IU daily for 12 months (Group 1) 
or 1,000 IU/day during the summer and fall and 2000 IU daily during the winter 
and spring (Group 2). They varied the dose of Vitamin d received to take into 
account the fluctuation of UV radiation throughout the year. The results 
demonstrated that even the highest dose regimen (2,000 IU daily) could not 
maintain patients’ serum Vitamin D greater than 32 ng/mL, below the optimal 
therapeutic target of 40-60 ng/mL.  
 Another study, by Kojecky et al. (2016), also investigated the effects of 
vitamin D supplementation (1100 IU, daily) in a group of patients with IBD 
compared to a control group of IBD patients. As in the previous study, the 
researchers found no statistically significant difference (p > 0.05) in the serum 





Figure 6. Comparison of Serum Vitamin D in Supplemented vs. Unsupplemented 
Group. Taken from (Kojecky, Adamikova, and Klimek 2016). 
Conversion between vitamin D measurements: 1 ng/mL = 2.5 nmol/mL 
 Both Pappa et al. (2014) and Kojecky et al. (2016) postulated that the 
ineffectiveness of daily vitamin D dosing to raise and maintain serum Vitamin D 
levels might be due to the low bioavailability of Vitamin D in patients with IBD. 
It has been determined that IBD prevents normal Vitamin D absorption, 
depending on disease location or previous surgery.  The ability to absorb 




et al. 2011). This conclusion supports the hypothesis that patients with CD and 
UC may need higher doses of Vitamin D to combat their impaired ability to 
absorb it in the gastrointestinal tract.  
 
High Daily Supplementation  
 Based on the aforementioned low-dose supplementation studies, a 400-
2,000 IU daily dosing regimen of Vitamin D is too low to observe a meaningful 
increase in serum Vitamin D and does not provide any therapeutic benefits to the 
patients. Other studies have kept the same methodology of administering daily 
Vitamin D but at a greater concentration or dose. The first of these studies 
employed high dose (5,000 IU) Vitamin D (Yang et al. 2013). Figure 7 
demonstrates the significant increase in serum Vitamin D patients experienced 






Figure 7. Effects of 5000 IU/day Vitamin D Supplementation on Serum Vitamin D 
levels. Taken from (Yang et al. 2013). 
(a) A Vitamin D dose of 5,000 IU/day significantly raised serum 25(OH)D and the final 
mean above 40 ng/mL. 
(b) First and final values of serum 25(OH)D are reported for each patient. 
(c) Throughout the supplementation regimen, serum 25(OH)D continued to rise. 
 
Not only were the researchers successful in raising serum 25(OH)D levels, but 
the patients with CD recorded improved Clinical Disease Activity Index (CDAI) 
and Quality of Life scores. On the other hand, this higher daily dose did not 
significantly reduce TNF-alpha or IL-17 measured in the patients’ blood.  These 
data demonstrate that measured Vitamin D blood levels were not related to 
concurrent inflammatory cytokine levels.  
 In another study, researchers adjusted daily Vitamin D dosing for their 




Patients started with either a daily 5,000 IU or 10,000 IU regimen and adjusted 
their dosage every four weeks if their serum 25(OH)D changed. Figure 8 
demonstrates the timeline and change in Vitamin D dosage throughout the 16-
week study. 
 
Figure 8. Study timeline and changes in Vitamin D regimen. Taken from (Garg et al. 
2018). 
 
Tailoring Vitamin D dosing for each subject enabled the researchers to raise and 
maintain sufficient serum Vitamin D levels in their patients. On average, serum 




disease activity fell during the 12-week interval. However, this did not translate 
into a decrease in fecal calprotectin or other inflammatory biomarkers. It is 
possible that the12-week study period was insufficient to manifest a reduction in 
biomarkers of mucosal inflammation. Moreover, this study only recruited ten 
patients, 5 with CD and 5 with UC, which did not afford sufficient statistical 
power to meaningfully assess changes in disease activity in patients with IBD. 
 
Compliance Issues with Daily Vitamin D Supplementation 
 A key issue in daily vitamin D supplementation in the pediatric 
population is compliance. In all of the aforementioned daily Vitamin D regimen 
studies, a significant number of subjects were excluded because they did not 
fully adhere to daily Vitamin D intake. A separate study focusing on medication 
compliance in the pediatric population found decreased medication adherence in 






Figure 9. Medication adherence across three pediatric populations. Taken from 
(LeLeiko et al. 2013). 
 5-ASA and 6-MP are maintenance medications used in pediatric subjects 
in this study. The difference in daily drug compliance across the three groups 
may be attributable to factors such as greater parental support and oversight in 
the younger group and varying behavioral attributes during the adolescent 
years. Levels of compliance also impact the net effect of Vitamin D 
supplementation. Kojecky et al. (2016) observed that only 52.1% of their IBD 
patients fully complied with their prescribed daily dose of Vitamin D (1,100 IU) 




regimen (Kojecký et al. 2019). With half of the overall pediatric subject 
population neglecting to take their daily medication more than 80% of the time, 
GI clinicians must identify improved treatment regimens that facilitate 
compliance and decrease pill “fatigue.” If IBD patients do not perceive or 
experience a benefit from complying with their daily medication regimen, they 
are less likely to follow through with what their gastroenterologist prescribes 
them.  
 One approach to improve compliance would be to decrease reliance on 
treatment regimens that mandate daily doses in favor of more flexible regimens 
incorporating scheduled interval dosing. The next section will review findings 
from recent studies that have explored high-dose interval Vitamin D therapies in 




HIGH DOSE INTERVAL THERAPY 
Current medical guidelines published by multiple healthcare 
organizations cap the upper limit of daily Vitamin D supplementation at 4,000 IU 
for patients at least nine years old (Pilz et al. 2018). Adherence to this guideline 
should reduce the risks related to long-term hypervitaminosis D, including 
hypercalcemia, hypercalciuria, and nephrocalcinosis (Vogiatzi et al. 2014). While 
adverse effects related to Vitamin D administration are rare in children, clinicians 
should track serum and urine calcium to ensure that their prescribed Vitamin D 
dose does not result in hypercalcemia or hypercalciuria.  
Investigators and clinicians concerned about the risks associated with 
high-dose daily Vitamin D supplementation have explored high-dose interval 
therapies to more safely and effectively raise serum Vitamin D levels in pediatric 
patients with CD and UC. One of the first studies that examined the 
pharmacokinetics of high-dose (100,000 IU) Vitamin D demonstrated that a one-
time, high dose of Vitamin D was safe to administer in patients (Ilahi, Armas, 
and Heaney 2008). They collected subjects’ serum to observe mean changes in 





Figure 10. Serum 25(OH)D over time after one 100,000 IU dose. Taken from (Ilahi, 
Armas, and Heaney 2008). 
 
As shown in the above figure, the high dose of Vitamin D was also effective at 
raising and maintaining serum 25(OH)D at levels above 32 ng/mL for over 60 
days on average. These results supported exploring other alternative interval 
dosing regimens to raise and maintain serum Vitamin D to therapeutic levels. 
The number of research groups investigating the safety and efficacy of Vitamin D 
supplementation in pediatric patients has risen considerably in the last ten years.  
For the most part, these studies have demonstrated that higher, weekly, or 




2016). Vitamin D impacts directly on components of the innate and adaptive 
immune systems.   If a requirement on daily supplementation lowers overall 
compliance in children, high-dose interval supplementation has the potential to 
benefit pediatric patients with CD and UC by better supporting their immune 
system by optimizing their serum 25(OH)D levels. 
 
Studies using high dose interval therapy for autoimmune diseases 
 Autoimmune disorders, including IBD, multiple sclerosis, and lupus, 
arthritis, are becoming increasingly prevalent.  Patients with autoimmune 
disorders often exhibit concomitant Vitamin D deficiency.  This hypovitaminosis 
D appears to be associated with higher disease activity and systemic 
inflammatory cytokine levels. A key regulator in the adaptive immune response 
is the Treg cell.  This differentiated T cell suppresses inflammatory cytokine 
secretion. In a blinded and randomized study conducted in 60 healthy 
volunteers, levels of Treg cells were tracked at the beginning and end of a three-
month trial during which patients received a monthly dose (140,000 IU) of 




serum 25(OH)D and percentage of Treg cells in the vitD group, relative to that 
observed in the placebo group. 
  
Figure 11. Increase in serum 25(OH)D and Treg cells. Adapted from (Prietl et al. 2014). 
A. The shaded box plots represent vitD group values, and the placebo group 
values are represented by the white box plots. **p < 0.005, ***p < 0.001 as 
compared to baseline. 
B. VitD group values (dark circles) compared to placebo group values (white 
circles). Correlation between change in serum 25(OH)D and change in 
percent of Treg cells. 
 
These results demonstrate that high dose monthly interval supplementation with 
Vitamin D improved adaptive immune responses by increasing the number of 
Treg cells, which is highly desirable for patients with autoimmune diseases. 
 Additional studies have investigated the effects of the high dose interval 




inflammatory diseases. One study investigated the immunological effects of 
weekly high-dose (50,000 IU) Vitamin D in a cohort of 580 female adolescents 
(Tabatabaeizadeh et al. 2017). They observed a significant reduction in 
inflammatory markers, including C-Reactive Protein (CRP) levels and neutrophil 
counts. CRP levels increase due to an increase in IL-6 cytokines and are 
attenuated by higher circulating serum levels of 25(OH)D. Neutrophils are a vital 
part of the innate immune system and contribute to acute inflammatory 
responses and associated tissue damage. Interestingly, investigators 
demonstrated that high-dose Vitamin D could suppress inflammatory cytokine 
production in this pediatric population. 
 Another study investigated the immunologic impact of three different 
Vitamin D dosing regimens in 154 patients with either inflammatory rheumatic 
disease or osteoarthritis over six months (Sainaghi et al. 2013). Table 3 









Table 3. Treatment types and results from (Sainaghi et al. 2013) 
Treatment Type Treatment Details Mean Serum 25(OH)D 
after 6 months 
High-dose loading 
treatment (HLT) 
Initial, single 300,000 IU 
dose, followed by daily 
800-1000 IU dose 
ARD – 73.9 nmol/L 
NARD - 82.9 nmol/L 
Low-dose loading 
treatment (LLT) 
Initial, single 100,000 IU 
dose, followed by daily 
800-1000 IU dose 
ARD – 68.6 nmol/L 
NARD - 75.6 nmol/L 
Standard Treatment (ST) Daily 800-1000 IU dose ARD – 59.4 nmol/L 
NARD – 61.6 nmol/L 
 
Treatment with each of the three study regimens significantly (p<0.001) increased 
plasma 25(OH)D over baseline.  HLT was the most effective at raising serum 
25(OH)D.  A greater percentage of patients in the HLT group experienced a 
normalization in their serum 25(OH)D and parathyroid hormone levels, 
indicating that the HLT effectively increased and maintained serum 25(OH)D 
levels.  
 Overall, data from the three studies discussed in this section demonstrate 
that a high dose Vitamin D therapy can raise and maintain serum 25(OH)D 
levels, promote the proliferation of anti-inflammatory T cells, and lower levels of 




could be a safe and effective adjunct therapy in pediatric patients with CD and 
UC.  
 
High Dose Interval Therapy for Pediatric Patients with IBD 
 Few studies have performed high Vitamin D dose interval therapies for 
pediatric patients with IBD. However, preliminary data appear promising. A 
prospective study using data collected from 44 patients compared a weekly 
dosing regimen of 50,000 IU over six weeks to a stoss dosing regimen, 
administering a single dose of 300,000 IU (Lee et al. 2020). Figure 12 summarizes 
their findings concerning serum levels of Vitamin D. In a stoss dosing regimen, a 
single, high-dose oral supplement is administered to subjects at the first visit. In 
subsequent visits, no more of the supplement is administered. As a result, 
studies with this paradigm investigate the therapeutic effect of a single, high 





Figure 12. Serum 25(OH)D levels measured over 12 weeks. Taken from (Lee et al. 
2020). 
Stoss therapy (black squares) and standard of care (white circles) groups exhibited 
similar levels of serum Vitamin D until a significant difference at week 12 (p < 0.05). 
 
The research group from Lee et al. (2020) thus demonstrated that the stoss 
therapy was similarly effective in raising and maintaining serum Vitamin D 
levels to that observed in patients receiving a weekly dosing regimen. These data 
support the hypothesis that interval high-dose Vitamin D therapy can improve 
levels and prevent the need for compliance-dependent daily dosing regimens.  
Pairing Vitamin D dosing with scheduled infliximab infusions provides an 
opportunity to even further improve patient compliance. However, the mean 
serum 25(OH)D level in the stoss group was lower than the level observed in the 




methodology.  Although patients’ age ranged from 6 to 21 years old, the 
principal investigators chose to administer the same dose (300,000 IU) to all 
patients, regardless of age or BMI. Future studies may demonstrate improved 
results using high-dose interval Vitamin D therapy by tailoring each patient's 
dosing regimen. Also, larger studies will be required to enable more definitive 
statements about Vitamin D's impact on children's immune function.    
A study that included 23 pediatric patients with IBD provided subjects 
with a single oral dose of Vitamin D dose based on age and varied from 100,000 
to 800,000 IU (Martin et al. 2019). Vitamin D toxicity in pediatric patients has 
been observed in response to doses of 40,000 to 560,000 IU/kg, and the doses 
employed in this study fell within this range (Vogiatzi et al. 2014). High-dose 
“Stoss” therapy of this type had previously been shown to be safe and effective 
in pediatric patients (Wallace et al. 2018) (Moslemi et al. 2018). Martin et al. 





Figure 13. Time after stoss therapy vs. serum 25(OH) D levels. Taken from (Martin et 
al. 2019). 
Serum values were determined over three visits – before stoss dosing, 1-2 months later, 
and 3-6 months after that. 
 
Investigators observed a significant decrease in PDCAI scores and disease 
activity. They also recorded significantly decreased markers of inflammation, 
including erythrocyte sedimentation rate (ESR), CRP, and platelet count. There 
were no accompanying changes in hematocrit or albumin. This observation is 




have failed to include its potential effect(s) on localized or systemic inflammatory 
responses.  
 
Vitamin D, COVID-19, and IBD 
 With the recent COVID-19 pandemic, there has been a greater push for 
more flexible care to prevent IBD patients from coming into the hospital more 
than they do. Moreover, many studies have been published correlating serum 
Vitamin D levels and the risk of developing severe COVID-19 symptoms. In a 
study with 185 patients, researchers determined a significant correlation between 
Vitamin D deficiency and the severity of COVID-19 outcome in patients 
(Radujkovic et al. 2020). Researchers compared Vitamin D sufficient and 
deficient patients across the entire cohort and within the inpatient group. Figure 
14 presents the study's main findings, and it demonstrates that those deficient in 
Vitamin D levels experience significantly higher cumulative incidence levels and 
significantly lower levels of survival. With the aforementioned vital role Vitamin 
D plays in the immune system, these results demonstrate the importance of 
supplementing vitamin D deficient patients to raise their serum Vitamin D levels 





Figure 14. Outcome of COVID groups divided based on Vitamin D status, <12 or >12 
ng/mL. Taken from (Radujkovic et al. 2020) 
A. Comparing cumulative incidence between Vitamin D deficient and sufficient 
groups across all study patients. 
B. Comparing survival probability between Vitamin D deficient and sufficient 
groups across all study patients. 
C. Comparing cumulative incidence between Vitamin D deficient and sufficient 
inpatient groups. 






Researchers also determined that Vitamin D supplementation reduced the 
risk of developing severe COVID-19 symptoms significantly (Rastogi et al. 2020). 
Asymptomatic and mildly symptomatic COVID-19 positive patients were 
recruited to either received placebo or high dose Vitamin D drops (60,000 IU) 
over seven days. Most participants in the intervention group reached Vitamin D 
levels greater than 50 ng/mL, expressed decreased fibrinogen levels, an 
inflammatory marker, and reached COVID-19 negative status faster than 
participants in the placebo group. Interestingly, levels of other inflammatory 
markers such as D-dimer, C-reactive protein, and procalcitonin did not decrease, 
which indicates the need for further research into the effect of Vitamin D 
supplementation on more pro-inflammatory markers. Table 4 briefly 
summarizes the study’s findings on Vitamin D and fibrinogen levels. These 
findings further showcase the effectiveness of high dose Vitamin D 









Table 4. Change in the levels of serum Vitamin D and inflammatory markers. 
Taken from (Rastogi et al. 2020). 





Δ Vitamin D (ng/ml) 42.4 (39 to 48.8) 5.1 (0 to 12.3) <0.001* 
Δ Fibrinogen (ng/ml) −0.9 (−2.0 to −1.0) −0.04 (−1.02 to 0.0) 0.001* 
 
*p<0.05 considered significant 
 
 Although the pediatric population has fared well clinically, even with 
active COVID-19 infections, the IBD subpopulation is at greater risk of 
developing more severe COVID-19 symptoms due to the immunosuppressive 
therapies they receive (Beaugerie, Rahier, and Kirchgesner 2020). Because of the 
immunosuppressive therapies, IBD patients have a greater risk of contracting 
other viruses and easily transmittable diseases besides COVID-19. Thus, there is 
a greater need for pediatric IBD patients to equip their immune systems against 
current and future harmful antigens. Since Vitamin D plays an active role in the 
anti-inflammatory response, reaching optimal serum Vitamin D levels could 
prime patients to overcome outbreaks occurring throughout the general 




patients from external antigens drives the need for an effective Vitamin D 






CONCLUSION AND FUTURE DIRECTIONS 
 High dosing regimens of vitamin D in the IBD pediatric population were 
both safe and effective. The prevalence of IBD is concentrated in northern, 
industrialized regions, where exposure to UV radiation is significantly reduced. 
For patients with IBD living in these regions, the reduced amount of sun 
exposure likely contributes to their low serum 25(OH)D status. Moreover, during 
periods of high disease activity, patients with IBD do not absorb nutrients, 
including vitamin D, effectively. The insufficient serum levels of 25(OH)D may 
also contribute to the higher risk of colorectal cancer observed in these patients. 
Vitamin D has been shown to decrease inflammatory markers, such as IL-17, IL-
6, and inflammatory T cells, and promote anti-inflammatory markers, such as IL-
10, Treg cells, and Th2 cells. For these reasons, research developing new 
treatment paradigms to maintain adequate vitamin D levels could be beneficial 
to the immune system of current and future IBD patients. 
 Additionally, studies need to be more consistent when collecting data. 
Comparing research studies from various countries is nearly impractical since 
each study group has varying methods on the age of the population they are 
studying. As a result, international studies should be conducted to assess the 




severity of symptoms. Moreover, in countries where IBD prevalence is rising, 
such as India and Japan, researchers should more definitively determine which 
populations are most affected. Therefore, they could present a more substantial 
theory correlating the severity of IBD with the population’s location, time spent 
outdoors, and diet. 
 Existing studies investigating vitamin D supplementation in patients with 
IBD patients range from daily, low-dose regimens to high-dose weekly or stoss 
dosing regimens. High dose regimens were effective at raising and maintaining 
optimal serum vitamin D levels.  Some studies further demonstrated 
improvements in inflammation. These data support studies that improve 
compliance.  Interval vitamin D supplementation is one example demonstrating 
the benefit of high dose interval therapy coincident with scheduled monthly or 
bi-monthly drug infusions.  
Few studies have focused on high-dose vitamin D treatment regimens in 
children with IBD.  A greater number of pediatric patients with IBD need to be 
recruited in future studies to determine the most effective dosing, based on 
various crucial factors, such as BMI and age. These studies also should be more 
consistent about including measurements of inflammatory markers to more 




modulation of the innate and adaptive immune systems. Finally, patients should 
be monitored over longer intervals. With high-dose vitamin D therapy 
administration to patients at each visit, investigators can track the rise to steady-
state serum 25(OH)D levels. Existing data suggest that the future of vitamin D 
treatment is promising and may play a role in managing children and adults 
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